Prostaglandin D2 (PGD2) antagonists may be useful antivirals for the treatment of viral bronchiolitis and possibly as primary preventatives for asthma. Queensland-led research has shown that respiratory syncytial virus (RSV) infection up-regulates hematopoietic prostaglandin D synthase expression resulting in PGD2 release by airway epithelial cells. They also found PGD2 production was elevated in nasopharyngeal samples ...
Already a member?
Enter your email to keep reading.